CEO, Quench Bio, Cambridge, MA
Board Chair: Elected 2015
Chair of the Board 2020–present
AB Dartmouth College
BE Thayer School of Engineering
MBA Tuck School of Business
Samantha Truex is CEO of Quench Bio, a discovery stage start-up developing medicines for inflammatory diseases. She is also an entrepreneur-in-residence at Atlas Venture and serves on the board of Hotspot Therapeutics. Sam has 25 years of biotech experience, including as COO and head of corporate development for Synlogic and as chief business officer for Padlock Therapeutics where she was integral to Padlock's operations and acquisition by Bristol-Myers Squibb. Sam previously spent several years each at Biogen and Genzyme. At Biogen, she served as vice president of corporate development, leading negotiations of multiple licensing, collaboration and acquisition transactions and serving as program executive during the launch, preclinical and early clinical phases of medications for hemophilia and MS. At Genzyme, she handled licensing and M&A transactions across multiple business units, including for Genzyme Molecular Oncology and Genzyme Genetics. Earlier in her career, Sam worked for Chiron and Health Advances.
In addition to being a member of the Thayer Board, Sam has previously served on the Corporate Collaboration Council advising Thayer's MEM program and on Dartmouth's Alumni Liaison Committee of the Alumni Council.